| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/29/2006 | EP1638606A2 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 03/29/2006 | EP1638605A2 Delivery of therapeutic compounds to the brain and other tissues |
| 03/29/2006 | EP1638601A1 Carrier proteins for vaccines |
| 03/29/2006 | EP1638595A1 Freeze-dried fsh / lh formulations |
| 03/29/2006 | EP1638539A1 Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug |
| 03/29/2006 | EP1638538A2 Dosage form |
| 03/29/2006 | EP1638534A1 Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a plga matrix |
| 03/29/2006 | EP1638530A2 Drug polymer complexes |
| 03/29/2006 | EP1638523A2 Formulations for coated microprojections containing non-volatile counterions |
| 03/29/2006 | EP1638519A2 Sustained release dosage forms of anesthetics for pain management |
| 03/29/2006 | EP1638510A2 Multivalent carriers of bi-specific antibodies |
| 03/29/2006 | EP1638491A2 Deployable multifunctional hemostatic agent |
| 03/29/2006 | EP1638460A1 Directing cells to target tissues or organs |
| 03/29/2006 | EP1501806B1 Preparations for the topical application of anti-androgenically active substances |
| 03/29/2006 | EP1443917B1 Tamsulosin tablets |
| 03/29/2006 | EP1414408B1 Composition comprising paroxetine and a pharmaceutically acceptable glycyrrhizinate salt |
| 03/29/2006 | EP1347765B1 Dermatological aqueous formulations containing clindamycin and a water soluble zinc salt |
| 03/29/2006 | EP1284718B1 Occlusive transdermal therapeutic system wit a non-occlusive backing layer |
| 03/29/2006 | EP1283700B1 Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
| 03/29/2006 | EP1251750B1 Improved pediatric formula and methods for providing nutrition and improving tolerance |
| 03/29/2006 | EP1230267B1 Membrane translocating peptide drug delivery system |
| 03/29/2006 | EP1210113B1 Combined vaccine compositions |
| 03/29/2006 | EP1181376B1 Gene construct for prodrug activation encoding a heterologous, glycosylphophatidylinositol-modified carboxypeptidase g2 and a cell surface targeting signal peptide |
| 03/29/2006 | EP1165050B1 Methods for fine powder formation |
| 03/29/2006 | EP1156789B1 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 03/29/2006 | EP1133282A4 Taste masking rapid release coating system |
| 03/29/2006 | EP1124567B1 Buffered compositions for dialysis |
| 03/29/2006 | EP1105105B1 Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles |
| 03/29/2006 | EP1100468B1 Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| 03/29/2006 | EP1034180B1 Linker nucleoside, and production and use of the same |
| 03/29/2006 | EP1032647B1 Preservation of sensitive biological samples by vitrification |
| 03/29/2006 | EP1012331B1 Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| 03/29/2006 | EP0932388B1 Dosage form and method for administering drug |
| 03/29/2006 | EP0873749B1 Jellied medicinal composition for oral administration |
| 03/29/2006 | CN1753968A Antioxidative composition and composition for external use |
| 03/29/2006 | CN1753949A Poloxamer emulsion preparations |
| 03/29/2006 | CN1753691A Subcutaneously-administered ganglioside-based vaccine compositions |
| 03/29/2006 | CN1753689A The use of cytochrome p450 enzyme cyp2wi as a drug traget for cancer therapy |
| 03/29/2006 | CN1753664A Skin-whitening composition |
| 03/29/2006 | CN1753656A Bioadhesive liquid composition which is substantially free of water |
| 03/29/2006 | CN1753618A Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| 03/29/2006 | CN1751741A Nano carbon tube infusion agent, its prepn. method and application in treating cancer, cardiovascular disease and infectious disease |
| 03/29/2006 | CN1247263C Chitosan microcapsule, its preparation method and uses |
| 03/29/2006 | CN1247262C Adjuvant and vaccine composition containing monophosphoryl lipid A |
| 03/29/2006 | CN1247254C Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 03/29/2006 | CN1247194C Nagelinai clathrate compound |
| 03/29/2006 | CN1247193C Eye drops |
| 03/29/2006 | CN1247188C Medicinal composition |
| 03/29/2006 | CN1247179C Method for producing solid oral preparation form with continuous released active components |
| 03/28/2006 | US7019117 Immobilization hemoglobin protein with polyoxyethylene glycol |
| 03/28/2006 | US7019113 Reversible modification of membrane interaction |
| 03/28/2006 | US7019106 Lactic acid polymer and process for producing the same |
| 03/28/2006 | US7019067 Polymer powders, pressure sensitive adhesives and methods of making the same |
| 03/28/2006 | US7019061 For silicone-free cosmetics, drugs |
| 03/28/2006 | US7018980 Dissolving drug in acidic aqueous buffered solution; adding surfactant and oil; agitation; oral administering |
| 03/28/2006 | US7018825 DNase liquid solutions |
| 03/28/2006 | US7018658 Pharmaceutical pellets comprising tamsulosin |
| 03/28/2006 | US7018656 Gel formulations of 1-hydroxy-2(H)pyridone derivatives, which contain solvents and hydrophilic gel-forming agents |
| 03/28/2006 | US7018655 Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions |
| 03/28/2006 | US7018654 Pharmaceutical composition containing an active agent in an amino acid copolymer structure |
| 03/28/2006 | US7018645 biodegradable and water soluble polyesterether block polymers used for drug delivery |
| 03/28/2006 | US7018633 Selective destruction of cells infected with human immunodeficiency virus |
| 03/28/2006 | US7018624 Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
| 03/28/2006 | US7018621 dosage form serotonin agonists comprising aerosols formed by heating layers of the drugs on solid supports, to form vapors, then condensing to form condensates which can be administered by breathing; prophylaxis of headaches |
| 03/28/2006 | US7018620 Delivery of beta-blockers through an inhalation route |
| 03/28/2006 | US7018619 Administering a therapeutic amount of an alprazolam, estazolam, midazolam or triazolam condensation aerosol for therapy of anxiety or insomnia |
| 03/28/2006 | US7018618 An aerosol solution composition for use in an aerosol inhaler comprises an active material, a propellant containing a hydrofluoroalkane, a cosolvent and optionally a low volatility component to increase the mass median aerodynamic diameter of |
| 03/28/2006 | US7018609 For drug delivery |
| 03/28/2006 | US7018395 to destroy or impair target cells expressing a vascular endothelial growth factor (VEGF) receptor by administering a liposome system of conjugated antibodies, conjugated photosensitizer and another liposome conjugate and using light of an intensity such that nontarget cells are not destroyed |
| 03/28/2006 | CA2278744C Continuous microsphere process |
| 03/28/2006 | CA2106719C Reshaped monoclonal antibodies against an immunoglobulin isotype |
| 03/23/2006 | WO2006032018A2 Highly-aqueous non-respirable aerosols containing biologically-active ingredients method of making and device therefor |
| 03/23/2006 | WO2006031848A2 Corticosteroid topical dispersion with low content of surfactant |
| 03/23/2006 | WO2006031653A2 Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates |
| 03/23/2006 | WO2006031191A1 Compositions comprising compounds capable of forming a reversible bond or association with gaseous nitric oxide |
| 03/23/2006 | WO2006031142A1 Biologically active material, method for the production thereof and a therapeutic agent based thereon |
| 03/23/2006 | WO2006030887A1 External preparation for treating skin ulcer |
| 03/23/2006 | WO2006030851A1 Pirenoxine suspension type eye lotion |
| 03/23/2006 | WO2006030826A1 Medicinal composition |
| 03/23/2006 | WO2006030730A1 Permucosal composition and method of improving permucosal absorption |
| 03/23/2006 | WO2006030450A2 Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy |
| 03/23/2006 | WO2006030283A1 Process for the preparation of a polymeric hydrogel based on a highly purified polyvinylalcohol and uses thereof |
| 03/23/2006 | WO2006030217A2 Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs |
| 03/23/2006 | WO2006030013A1 The modulation of phagocytosis in neurons |
| 03/23/2006 | WO2006029579A1 Oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, method for producing and use as medicament thereof |
| 03/23/2006 | WO2006029554A1 Vascular embolus of paclitaxel-sodium alginate microsphere and its preparation |
| 03/23/2006 | WO2005118642A3 Bispecific fusion antibodies with enhanced serum half-life |
| 03/23/2006 | WO2005110491A8 Inducible dimerization of growth factor receptors for treating cancer |
| 03/23/2006 | WO2005105141A3 Combined meningococcal conjugates with common carrier protein |
| 03/23/2006 | WO2005094785A3 Compositions capable of facilitating penetration across a biological barrier |
| 03/23/2006 | WO2005079749A3 Chitosan containing solution |
| 03/23/2006 | WO2005072779A3 Growth factor-binding compounds attached to a calixarene |
| 03/23/2006 | WO2005058967A3 Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
| 03/23/2006 | WO2005058366A3 Compositions comprising two different populations of polymer-active agent conjugates |
| 03/23/2006 | WO2005048985A3 Alpha 1-antitrypsin compositions and treatment methods using such compositions |
| 03/23/2006 | WO2005048949A3 Rescue agents for treating botulinum toxin intoxications |
| 03/23/2006 | WO2004110585A9 Radial spherical crystallization product, process for producing the same and dry powder preparation containing the crystallization product |
| 03/23/2006 | WO2004096254A3 Transferrin conjugates for tumor treatment |
| 03/23/2006 | WO2004096117A3 Drug delivery systems comprising transferrin-nucleic acid conjugates |
| 03/23/2006 | WO2004073659A3 HIV gp120 MIMOTOPE ANTIGEN |